EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
S1	1	"6596900".pn.	US-PGPUB; USPAT; EPO	OR	ON	2006/08/25 06:11

```
Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:ssptamxg1614

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1          Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2          "Ask CAS" for self-help around the clock
 NEWS  3  FEB 27  New STN AnaVist pricing effective March 1, 2006
 NEWS  4  APR 04  STN AnaVist $500 visualization usage credit offered
 NEWS  5  MAY 10  CA/CAplus enhanced with 1900-1906 U.S. patent records
 NEWS  6  MAY 11  KOREAPAT updates resume
 NEWS  7  MAY 19  Derwent World Patents Index to be reloaded and enhanced
 NEWS  8  MAY 30  IPC 8 Rolled-up Core codes added to CA/CAplus and
                  USPATFULL/USPAT2
 NEWS  9  MAY 30  The F-Term thesaurus is now available in CA/CAplus
 NEWS 10  JUN 02  The first reclassification of IPC codes now complete in
                  INPADOC
 NEWS 11  JUN 26  TULSA/TULSA2 reloaded and enhanced with new search and
                  and display fields
 NEWS 12  JUN 28  Price changes in full-text patent databases EPFULL and PCTFULL
 NEWS 13  JUl 11  CHEMSAFE reloaded and enhanced
 NEWS 14  JUl 14  FSTA enhanced with Japanese patents
 NEWS 15  JUl 19  Coverage of Research Disclosure reinstated in DWPI
 NEWS 16  AUG 09  INSPEC enhanced with 1898-1968 archive

 NEWS EXPRESS  JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8
 NEWS X25      X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 06:01:18 ON 25 AUG 2006

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.63       0.63

FILE 'REGISTRY' ENTERED AT 06:03:09 ON 25 AUG 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
```

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 23 AUG 2006 HIGHEST RN 904004-64-4
DICTIONARY FILE UPDATES: 23 AUG 2006 HIGHEST RN 904004-64-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Documents and Settings\mgraffeo\My Documents\Critical
Data\10726878\cmp 1.str

chain nodes :
8 9 10 11
ring nodes :
1 2 3 4 5 6 7
chain bonds :
6-8 6-10 8-9 10-11
ring bonds :
1-2 1-5 2-3 3-4 3-6 4-5 4-7 6-7
exact/norm bonds :
1-2 1-5 2-3 3-4 3-6 4-5 4-7 6-7 8-9
exact bonds :
6-8 6-10 10-11

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:CLASS 9:CLASS 10:CLASS
11:CLASS

L1 STRUCTURE UPLOADED

=> s l1
SAMPLE SEARCH INITIATED 06:03:30 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 108 TO ITERATE

100.0% PROCESSED 108 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 1537 TO 2783
PROJECTED ANSWERS: 1 TO 80

L2 1 SEA SSS SAM L1

=> s l2 full
FULL SEARCH INITIATED 06:03:35 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 2148 TO ITERATE

100.0% PROCESSED 2148 ITERATIONS 9 ANSWERS
SEARCH TIME: 00.00.01

L3 9 SEA SSS FUL L1

=> d 1-9

L3 ANSWER 1 OF 9 REGISTRY COPYRIGHT 2006 ACS on STN
RN 709046-36-6 REGISTRY
ED Entered STN: 14 Jul 2004
CN Bicyclo[3.2.0]heptane-6-acetic acid, 6-(aminomethyl)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C10 H17 N O2
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 2 OF 9 REGISTRY COPYRIGHT 2006 ACS on STN
RN 473924-35-5 REGISTRY
ED Entered STN: 19 Nov 2002
CN Bicyclo[3.2.0]heptane-6-acetic acid, 6-(aminomethyl)-, (1S,5S,6R)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C10 H17 N O2
CI COM
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

6 REFERENCES IN FILE CA (1907 TO DATE)
6 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 3 OF 9 REGISTRY COPYRIGHT 2006 ACS on STN
RN 473924-33-3 REGISTRY
ED Entered STN: 19 Nov 2002
CN Bicyclo[3.2.0]heptane-6-acetic acid, 6-(aminomethyl)-, (1R,5R,6S)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN [(1R,5R,6S)-6-(Aminomethyl)bicyclo[3.2.0]hept-6-yl]acetic acid
FS STEREOSEARCH
MF C10 H17 N O2
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

22 REFERENCES IN FILE CA (1907 TO DATE)
22 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 4 OF 9 REGISTRY COPYRIGHT 2006 ACS on STN
RN 473829-56-0 REGISTRY
ED Entered STN: 18 Nov 2002
CN Bicyclo[3.2.0]heptane-6-acetic acid, 6-(aminomethyl)-, (1R,5R,6R)-rel- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C10 H17 N O2
CI COM
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 5 OF 9 REGISTRY COPYRIGHT 2006 ACS on STN
RN 473829-38-8 REGISTRY
ED Entered STN: 18 Nov 2002
CN Bicyclo[3.2.0]heptane-6-acetic acid, 6-(aminomethyl)-, (1R,5R,6R)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C10 H17 N O2
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 6 OF 9 REGISTRY COPYRIGHT 2006 ACS on STN
RN 473829-37-7 REGISTRY
ED Entered STN: 18 Nov 2002
CN Bicyclo[3.2.0]heptane-6-acetic acid, 6-(aminomethyl)-, (1S,5S,6S)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C10 H17 N O2
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 7 OF 9 REGISTRY COPYRIGHT 2006 ACS on STN
RN 473829-34-4 REGISTRY
ED Entered STN: 18 Nov 2002
CN Bicyclo[3.2.0]heptane-6-acetic acid, 6-(aminomethyl)-, hydrochloride,

(1R,5R,6R)-rel- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C10 H17 N O2 . Cl H
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL
CRN (473829-56-0)

Relative stereochemistry.



● HCl

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 8 OF 9 REGISTRY COPYRIGHT 2006 ACS on STN
RN 473829-33-3 REGISTRY
ED Entered STN: 18 Nov 2002
CN Bicyclo[3.2.0]heptane-6-acetic acid, 6-(aminomethyl)-, hydrochloride, (1S,5S,6R)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C10 H17 N O2 . Cl H
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL
CRN (473924-35-5)

Absolute stereochemistry. Rotation (+).



● HCl

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 9 OF 9 REGISTRY COPYRIGHT 2006 ACS on STN

RN 473829-32-2 REGISTRY
ED Entered STN: 18 Nov 2002
CN Bicyclo[3.2.0]heptane-6-acetic acid, 6-(aminomethyl)-, hydrochloride,
    (1R,5R,6S)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C10 H17 N O2 . Cl H
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL
CRN (473924-33-3)

Absolute stereochemistry. Rotation (-).



● HCl

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	184.48	185.11

FILE 'CAPLUS' ENTERED AT 06:04:08 ON 25 AUG 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 25 Aug 2006 VOL 145 ISS 9
FILE LAST UPDATED: 23 Aug 2006 (20060823/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4 22 L3

```
=> s l4 and (erectile or ejaculation)
          2587 ERECTILE
          1800 EJACULATION
L5           1 L4 AND (ERECTILE OR EJACULATION)

=> d bib abs

L5   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2006 ACS on STN
AN   2004:531342  CAPLUS
DN   141:88858
TI   A preparation of aminocarboxylic acid derivatives as alpha-2-delta
     ligands, useful for the treatment of sexual dysfunction
IN   Taylor, Charles Price, Jr; Thorpe, Andrew John; Van Der Graaf, Pieter
     Hadewijn; Wayman, Christopher Peter; Wustrow, David Juergen
PA   Warner-Lambert Company LLC, USA
SO   PCT Int. Appl., 39 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 9
     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
PI   WO 2004054563         A1    20040701    WO 2003-IB5682          20031203
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
             GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
             LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
             OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
             TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
             ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
             TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     CA 2451267           AA    20040613    CA 2003-2451267         20031127
     US 2004176456        A1    20040909    US 2003-726878          20031202
     CA 2509611           AA    20040701    CA 2003-2509611         20031203
     AU 2003283708        A1    20040709    AU 2003-283708          20031203
     EP 1572183           A1    20050914    EP 2003-775689          20031203
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     BR 2003016753        A     20051025    BR 2003-16753           20031203
     CN 1726015           A     20060125    CN 2003-80105968        20031203
     CN 1726021           A     20060125    CN 2003-80106009        20031203
     JP 2006515587        T2    20060601    JP 2004-560041          20031203
     US 2004132636        A1    20040708    US 2003-731605          20031209
     US 2004180958        A1    20040916    US 2003-732613          20031210
     US 2004143014        A1    20040722    US 2003-735398          20031212
PRAI US 2002-433491P      P     20021213
     GB 2003-2657         A     20030205
     US 2003-454074P      P     20030312
     WO 2003-IB5682       W     20031203
OS   MARPAT 141:88858
GI
```



I



II

AB The invention relates to a preparation of aminocarboxylic acid derivs., e.g. I [wherein: R1, R2, R3, R4, R5, R6, R7, and R8 are independently selected from H or C1-6alkyl, or R8 and R6 or R6 and R4 are taken together to form C3-7 cycloalkyl ring, etc.; n = 0-2; X is a carboxylic acid or carboxylic acid bioisostere], as alpha-2-delta ligands, useful for the treatment of premature ejaculation. For instance, delayed ejaculation in the presence of alpha-2-delta ligand II and effect of compound II on copulatory behavior in rapid ejaculating rats were demonstrated. Compound II increased ejaculation latency by 58% in rapidly ejaculating conscious rats.

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	7.56	192.67

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.75	-0.75

FILE 'STNGUIDE' ENTERED AT 06:05:31 ON 25 AUG 2006
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Aug 18, 2006 (20060818/UP).

=> s l4
SUBSTANCE QUERIES NOT VALID IN THIS FILE
The logic expression entered contains L#s or saved query names which correspond to structures built by the STRUCTURE command or to screen sets. These must be searched in a substance file such as the REGISTRY file. In some files you may use a Registry Number answer set from a structure search as a search term or profile in some bibliographic file containing Registry Numbers, e.g. the CA file. For an explanation, enter "HELP CROSSOVER" at an arrow prompt (=>).

=> FIL CAPLUS

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.42	193.09

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-0.75

FILE 'CAPLUS' ENTERED AT 06:09:39 ON 25 AUG 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907 - 25 Aug 2006 VOL 145 ISS 9
FILE LAST UPDATED: 23 Aug 2006 (20060823/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> DIS L4 1 IBIB IABS
THE ESTIMATED COST FOR THIS REQUEST IS 2.74 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L4 ANSWER 1 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1170963 CAPLUS
DOCUMENT NUMBER: 143:440755
TITLE: Combinations comprising α-2-δ ligands and NMDA receptor antagonists
INVENTOR(S): Hizue, Masanori; Imai, Aki; Toide, Katsuo
PATENT ASSIGNEE(S): Pfizer Japan, Inc., Japan; Pfizer Inc.
SOURCE: PCT Int. Appl., 69 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005102390	A2	20051103	WO 2005-IB988	20050411
WO 2005102390	A3	20060511		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2004-564374P P 20040422
ABSTRACT:
The invention relates to a synergistic combination of an α-2-δ ligand and an NMDA receptor antagonist (preferably an NR2B antagonist) or pharmaceutically-acceptable salts, esters or pharmaceutical compns. and their use in the treatment of pain, particularly neuropathic pain, and disorders of the central nervous system. Synthetic examples describe the preparation of α-2-δ ligands, e.g., (3R,4R,5R)-3-amino-4,5-dimethylheptanoic acid, useful in the combinations of the invention. The combination of 3-methylgabapentin as α-2-δ ligand and (-)-(R)-6-[2-[4-(3-fluorophenyl)-4-hydroxy-1-piperidinyl]-1-hydroxyethyl]-3,4-dihydro-2(1H)-quinolinone as NR2B antagonist produced synergy in ability to relieve neuropathic pain.

=> DIS L4 2 IBIB IABS
THE ESTIMATED COST FOR THIS REQUEST IS 2.74 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L4 ANSWER 2 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1170698 CAPLUS
DOCUMENT NUMBER: 143:446634
TITLE: Combinations comprising EP4-receptor antagonists and α2δ ligands for treating pain
INVENTOR(S): Audoly, Laurent Pascal
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 267 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005102389	A2	20051103	WO 2005-IB935	20050408

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2004-563863P P 20040420
ABSTRACT:
The present invention relates to a combination of an EP4-receptor antagonist (e.g. 4-[[[[5-fluoro-2-(4-fluorophenoxy)pyridin-3-yl]carbonyl]amino]methyl]benzoic acid) and an α2δ ligand (e.g. pregabalin), and pharmaceutically acceptable salts thereof, pharmaceutical compns. thereof and their use in the treatment of pain, particularly inflammatory, neuropathic, visceral and nociceptive pain. Although neither the compds. nor the methods of preparation are claimed, many example prepns. (many of which are reproduced from previously published patents) are included. 4-[(1S)-1-[[[5-chloro-2-(3-fluorophenoxy)pyridin-3-yl]carbonyl]amino]ethyl]benzoic acid and pregabalin were tested for effectiveness against carrageenan-induced mech. hyperalgesia and the combination was significantly more effective than either substance alone.

=> DIS L4 3 IBIB IABS
THE ESTIMATED COST FOR THIS REQUEST IS 2.74 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L4 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1075617 CAPLUS
DOCUMENT NUMBER: 143:367000
TITLE: Preparation of atypical antipsychotics for combinations with α-2-δ ligands
INVENTOR(S): Field, Mark John; Williams, Richard Griffith
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2005092318	A1	20051006	WO 2005-IB510	20050224

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: GB 2004-5200 A 20040308
US 2004-560416P P 20040407

ABSTRACT:
The instant invention relates to a combination, particularly a synergistic combination, of an α-2-δ ligand and an atypical antipsychotic, and pharmaceutically acceptable salts thereof, pharmaceutical compns. thereof and their use in the treatment of pain, particularly neuropathic pain. (3R,4R,5R)-3-amino-4,5-dimethylheptanoic acid, an atypical antipsychotic, was prepared via a series of reactions starting with (S)-3-[(E)-2-methylpent-2-enoyl]-4-phenyloxazolidin-2-one. Example α-2-δ ligands include gabapentin.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> DIS L4 4 IBIB IABS
THE ESTIMATED COST FOR THIS REQUEST IS 2.74 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L4 ANSWER 4 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:493505 CAPLUS
DOCUMENT NUMBER: 143:32337
TITLE: Calcium carbonate for stabilizing solid pharmaceutical compositions of amino acids
INVENTOR(S): Razzano, Elena
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005051384	A1	20050609	WO 2004-IB3743	20041112

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: GB 2003-27389 A 20031125
US 2004-535845P P 20040112

OTHER SOURCE(S): MARPAT 143:32337
ABSTRACT:

The present invention relates to the use of calcium carbonate as a stabilizing agent in solid pharmaceutical compns. comprising an amino acid as the pharmaceutically active agent, to the stabilized pharmaceutical compns. resulting therefrom and processes for their preparation Thus, tablets were prepared containing (+)-(2S)-5-amino-2-[(1-n-propyl-1H-imidazol-4-yl)methyl]pentanoic acid (active component) 31.13 mg, microcryst. cellulose 32.31 mg, calcium carbonate 32.31 mg, croscarmellose sodium 3.00 mg, and magnesium stearate 1.25 mg. Tablets stored at 40° and 75% relative humidity for 12 wk showed the presence of 98.9% of the active component.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> DIS L4 5 IBIB IABS
THE ESTIMATED COST FOR THIS REQUEST IS 2.74 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L4 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:472159 CAPLUS
DOCUMENT NUMBER: 143:26627
TITLE: Preparation of 5,7-diaminopyrazolo[4,3-d]pyrimidines with phosphodiesterase-5 (PDE5) inhibiting activity
INVENTOR(S): Bell, Andrew Simon; Brown, David Graham; Dack, Kevin Neil; Fox, David Nathan Abraham; Marsh, Ian Roger; Morrell, Andrew Ian; Palmer, Michael John; Winslow, Carol Ann
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: PCT Int. Appl., 282 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005049616	A1	20050602	WO 2004-IB3747	20041112
WO 2005049616	C1	20060601		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004290643	A1	20050602	AU 2004-290643	20041112
CA 2546987	AA	20050602	CA 2004-2546987	20041112
EP 1689751	A1	20060816	EP 2004-798876	20041112
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU				
NL 1027568	A1	20050526	NL 2004-1027568	20041123
NL 1027568	C2	20051130		
US 2005245544	A1	20051103	US 2004-997191	20041124

PRIORITY APPLN. INFO.:	GB 2003-27319	A	20031124
	US 2004-535797P	P	20040112
	WO 2004-IB3747	W	20041112

OTHER SOURCE(S): MARPAT 143:26627
GRAPHIC IMAGE:



I



II

ABSTRACT:
Title compds. [I; R1 = (substituted) cyclic group; R2 = H, alkyl; R3, R4 = (substituted) alkyl, alkenyl, alkynyl, cycloalkyl; R5 = YCO2R15, YR16; R6 = H, (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, etc.; Y = bond, CH2OCH2, alkylene, cycloalkylene; R15 = H, (substituted) alkyl; R16 = tetrazolyl, trifluoromethyltriazolyl, methylsulfonyltriazolyl, etc.; dotted lines = double bonds to form an aromatic ring], were prepared Thus, title compound (II) (preparation
given) inhibited PDE-5 with IC50 = 0.075 nM.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> DIS L4 6 IBIB IABS
THE ESTIMATED COST FOR THIS REQUEST IS 2.74 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L4 ANSWER 6 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:259678 CAPLUS
DOCUMENT NUMBER: 142:341889
TITLE: Pharmaceuticals containing combinations of an acetylcholine esterase inhibitor and α-2-δ receptor ligands
INVENTOR(S): Field, Mark John; Williams, Richard Griffith
PATENT ASSIGNEE(S): UK
SOURCE: U.S. Pat. Appl. Publ., 25 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005065176	A1	20050324	US 2004-936416	20040908
CA 2539377	AA	20050331	CA 2004-2539377	20040908
WO 2005027975	A1	20050331	WO 2004-IB2981	20040908

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1667722 A1 20060614 EP 2004-769370 20040908
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
PRIORITY APPLN. INFO.: GB 2003-22140 A 20030922
WO 2004-IB2981 W 20040908

ABSTRACT:
The instant invention relates to a combination of α-2-δ ligand and an AChE inhibitor for use in therapy, particularly in the treatment of pain, particularly neuropathic pain. Particularly preferred α-2-δ ligands are gabapentin and pregabalin. Particularly preferred ACHE inhibitors are donepezil (Aricept), tacrine (Cognex), rivastigmine (Exelon), physostigmine (Synapton), galantamine (Reminyl), metrifonate (Promem), neostigmine (Prostigmin) and icopezil. Thus pessary compns. contained the above ingredient 250, anhydrous dextrose 380, potato starch 363, and Mg stearate 7 mg. The preparation of some of the compds. is given.

=> DIS L4 7 IBIB IABS
THE ESTIMATED COST FOR THIS REQUEST IS 2.74 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L4 ANSWER 7 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:238701 CAPLUS
DOCUMENT NUMBER: 142:316826
TITLE: A preparation of combinations comprising alpha-2-delta ligands and dual serotonin-noradrenaline reuptake inhibitors, useful for treatment of pain
INVENTOR(S): Dooley, David James; Field, Mark John; Williams, Richard Griffith
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 23 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005059715	A1	20050317	US 2004-935824	20040908
AU 2004271800	A1	20050324	AU 2004-271800	20040906
CA 2537402	AA	20050324	CA 2004-2537402	20040906
WO 2005025675	A1	20050324	WO 2004-IB2943	20040906

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1663398 A1 20060607 EP 2004-769341 20040906
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
PRIORITY APPLN. INFO.: US 2003-502556P P 20030912
WO 2004-IB2943 W 20040906

GRAPHIC IMAGE:



I

ABSTRACT:
The invention relates to a combination, particularly a synergistic combination, of an alpha-2-delta ligand and a dual serotonin-noradrenaline reuptake inhibitor (DSNRI) or one or both of a selective serotonin reuptake inhibitor (SSRI) and a selective noradrenaline reuptake inhibitor (SNRI), and pharmaceutically acceptable salts thereof, pharmaceutical compns. thereof and their use in the treatment of pain, particularly neuropathic pain (no biol. data). For instance, 3-amino-5-methyloctanoic acid hydrochloride (I•HCl) was prepared from (S)-citronellyl bromide in eight steps.

=> DIS L4 8 IBIB IABS
THE ESTIMATED COST FOR THIS REQUEST IS 2.74 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L4 ANSWER 8 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:162040 CAPLUS
DOCUMENT NUMBER: 142:233358
TITLE: Pharmaceutical composition using a nicotinic receptor partial agonist-α2δ ligand combination for the treatment of obesity or to facilitate or promote weight loss
INVENTOR(S): Coe, Jotham W.; O'Neill, Brian T.; Sands, Steven B.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 19 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005043406	A1	20050224	US 2004-870208	20040617
CA 2534271	AA	20050303	CA 2004-2534271	20040809
WO 2005018622	A1	20050303	WO 2004-IB2604	20040809
WO 2005018622	C1	20050428		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1658059	A1	20060524	EP 2004-744239	20040809
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				

PRIORITY APPLN. INFO.: US 2003-497353P P 20030822

WO 2004-IB2604 W 20040809

ABSTRACT:
Pharmaceutical compns. are disclosed for the treatment of obesity, an overweight condition and compulsive overeating. The pharmaceutical compns. are comprised of a therapeutically effective combination of a nicotinic receptor partial agonist and an α2δ ligand and a pharmaceutically acceptable carrier. The method of using these compds. is also disclosed.

=> DIS L4 9 IBIB IABS
THE ESTIMATED COST FOR THIS REQUEST IS 2.74 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L4 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:162035 CAPLUS
DOCUMENT NUMBER: 142:233377
TITLE: Pharmaceutical composition and method using a combination of an opioid receptor antagonist and an α2δ ligand for the prevention and treatment of addiction in a mammal
INVENTOR(S): Coe, Jotham Wadsworth; Iredale, Philip A.; McHardy, Stanton Furst; McLean, Stafford
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 15 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005043345	A1	20050224	US 2004-870821	20040617
CA 2535814	AA	20050303	CA 2004-2535814	20040809
WO 2005018670	A1	20050303	WO 2004-IB2602	20040809
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1658098	A1	20060524	EP 2004-744237	20040809
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				

PRIORITY APPLN. INFO.:
US 2003-497372P P 20030822
WO 2004-IB2602 W 20040809

ABSTRACT:
Pharmaceutical compns. are disclosed for the treatment of alc. or cocaine dependence or addiction, tobacco dependence or addiction, reduction of alc. withdrawal symptoms or aiding in the cessation or lessening of alc. use or substance abuse or other behavioral dependencies including gambling. The pharmaceutical compns. are comprised of a therapeutically effective combination of an opioid receptor antagonist and an α2δ ligand and a pharmaceutically acceptable carrier. The method of using these compds. is also disclosed.

=> DIS L4 10 IBIB IABS

THE ESTIMATED COST FOR THIS REQUEST IS 2.74 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L4 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:160850 CAPLUS
DOCUMENT NUMBER: 142:233374
TITLE: Pharmaceutical composition using a combination of a nicotinic receptor partial agonist and an α2δ ligand for the prevention and treatment of addiction in a mammal
INVENTOR(S): Coe, Jotham W.; Sands, Steven B.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 21 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005043407	A1	20050224	US 2004-879616	20040629
CA 2535811	AA	20050303	CA 2004-2535811	20040809
WO 2005018621	A1	20050303	WO 2004-IB2603	20040809
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1658058	A1	20060524	EP 2004-744238	20040809
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				

PRIORITY APPLN. INFO.: US 2003-497350P P 20030822
WO 2004-IB2603 W 20040809

ABSTRACT:
Pharmaceutical compns. are disclosed for the treatment of alc. or cocaine dependence or addiction, alc. dependence or addiction, reduction of alc. withdrawal symptoms or aiding in the cessation or lessening of tobacco use or substance abuse or other behavioral dependencies. The pharmaceutical compns. are comprised of a therapeutically effective combination of a nicotinic receptor partial agonist and an α2δ ligand and a pharmaceutically acceptable carrier. The method of using these compds. is also disclosed.

=> DIS L4 11 IBIB IABS
THE ESTIMATED COST FOR THIS REQUEST IS 2.74 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L4 ANSWER 11 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:17019 CAPLUS
DOCUMENT NUMBER: 142:107448
TITLE: Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
INVENTOR(S): Roark, William Howard
PATENT ASSIGNEE(S): Warner-Lambert Company LLC, USA
SOURCE: U.S. Pat. Appl. Publ., 44 pp.
CODEN: USXXCO

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005004177	A1	20050106	US 2004-883899	20040702
WO 2005002585	A1	20050113	WO 2004-IB2075	20040621
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1680125	A1	20060719	EP 2004-737084	20040621
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				

PRIORITY APPLN. INFO.: US 2003-484577P P 20030702
WO 2004-IB2075 W 20040621
OTHER SOURCE(S): MARPAT 142:107448
ABSTRACT:
This invention relates to a combination of an allosteric inhibitor of matrix metalloproteinase-13 (MMP-13), or a pharmaceutically acceptable salt thereof, and a ligand to an alpha-2-delta receptor, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the combination, and a method of using the combination to treat a disease or disorder in a mammal responsive to treatment in one aspect by an allosteric inhibitor of MMP-13 and in the same or a different aspect by a ligand to an alpha-2-delta receptor, such as cartilage damage and joint diseases. Preparation of 4-[[3-[2-(4-methoxybenzyl)-2H-tetrazol-5-yl]benzoylamino]methyl]benzoic acid as the allosteric inhibitor of MMP-13 is exemplified.

=> DIS L4 12 IBIB IABS
THE ESTIMATED COST FOR THIS REQUEST IS 2.74 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L4 ANSWER 12 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:965255 CAPLUS
DOCUMENT NUMBER: 141:410950
TITLE: Preparation of 5,7-diaminopyrazolo[4,3-d]pyrimidines as selective PDE5 inhibitors useful in the treatment of hypertension
INVENTOR(S): Bell, Andrew Simon; Brown, David Graham; Fox, David Nathan Abraham; Marsh, Ian Roger; Morrell, Andrew Ian; Palmer, Michael John; Winslow, Carol Ann
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: PCT Int. Appl., 279 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004096810	A1	20041111	WO 2004-IB1433	20040422
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
TD, TG

AU 2004234158	A1	20041111	AU 2004-234158	20040422
CA 2523831	AA	20041111	CA 2004-2523831	20040422
EP 1620437	A1	20060201	EP 2004-728868	20040422
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004009903	A	20060425	BR 2004-9903	20040422
CN 1780841	A	20060531	CN 2004-80011467	20040422
NL 1026074	A1	20041101	NL 2004-1026074	20040428
NL 1026074	C2	20050809		
US 2005043325	A1	20050224	US 2004-834484	20040429
NO 2005004404	A	20051124	NO 2005-4404	20050922

PRIORITY APPLN. INFO.:	GB 2003-9780	A	20030429
	GB 2003-27748	A	20031128
	US 2003-476678P	P	20030606
	US 2004-538147P	P	20040120
	WO 2004-IB1433	A	20040422

OTHER SOURCE(S): MARPAT 141:410950
GRAPHIC IMAGE:

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

ABSTRACT:
Title compds. I [wherein R1 = (un)substituted cycloalkyl, cycloalkenyl, (un)substituted pyridin-2-yl, (un)fused Ph, etc.; R2 = H, alkyl; R3, R4 = independently (un)substituted alkyl, alkenyl, cycloalkyl, etc.; or NR3R4 = piperazin-1-yl, monocyclic, saturated polycyclic; R5 = (un)substituted halo/alkyl, alkenyl, alkynyl, cycloalkyl; R6 = H, (un)substituted alkyl, haloalkyl, alkenyl, alkynyl, etc.] were prepared as selective PDE5 inhibitors. For example, II•2HCl was prepared from (4-Methylpyridin-2-yl)amine, dichloride III (general preparation given), and tert-Bu piperazine-1-carboxylate. I gave IC50 values < 10,000 nM in an in vitro assay for PDE5 inhibition. Thus, I are used for treating hypertension.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> DIS L4 13 IBIB IABS
THE ESTIMATED COST FOR THIS REQUEST IS 2.74 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L4 ANSWER 13 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:531356 CAPLUS
DOCUMENT NUMBER: 141:65106
TITLE: Calcium channel α-2-δ subunit ligands to treat chronic obstructive pulmonary disease (COCD), chronic cough, and other diseases
INVENTOR(S): Bertrand, Claude Philippe; Chovet, Maria Emilia Pereira Chicau; Geppetti, Pierangelo; Taylor, Charles Price, Jr.; Thorpe, Andrew John; Wustrow, David Juergen
PATENT ASSIGNEE(S): Warner-Lambert Company LLC, USA

SOURCE: PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004054577	A1	20040701	WO 2003-IB5640	20031203
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2451267	AA	20040613	CA 2003-2451267	20031127
US 2004176456	A1	20040909	US 2003-726878	20031202
AU 2003303037	A1	20040709	AU 2003-303037	20031203
CN 1726015	A	20060125	CN 2003-80105968	20031203
CN 1726021	A	20060125	CN 2003-80106009	20031203
US 2004132636	A1	20040708	US 2003-731605	20031209
US 2004180958	A1	20040916	US 2003-732613	20031210
US 2004143014	A1	20040722	US 2003-735398	20031212

PRIORITY APPLN. INFO.:

US 2002-433491P	P	20021213
GB 2003-2657	A	20030205
US 2003-454074P	P	20030312
WO 2003-IB5640	W	20031203

OTHER SOURCE(S): MARPAT 141:65106
ABSTRACT:
The invention discloses the use of an calcium channel α-2-δ subunit ligand in the treatment of chronic obstructive pulmonary disease (COPD) and diseases associated with a diagnosis of COPD, and particularly to the treatment of chronic cough, which may be unrelated to COPD. Compound preparation is included.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> DIS L4 14 IBIB IABS
THE ESTIMATED COST FOR THIS REQUEST IS 2.74 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L4 ANSWER 14 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:531342 CAPLUS
DOCUMENT NUMBER: 141:88858
TITLE: A preparation of aminocarboxylic acid derivatives as alpha-2-delta ligands, useful for the treatment of sexual dysfunction
INVENTOR(S): Taylor, Charles Price, Jr; Thorpe, Andrew John; Van Der Graaf, Pieter Hadewijn; Wayman, Christopher Peter; Wustrow, David Juergen
PATENT ASSIGNEE(S): Warner-Lambert Company LLC, USA
SOURCE: PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2004054563	A1	20040701	WO 2003-IB5682		20031203
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2451267	AA	20040613	CA 2003-2451267		20031127
US 2004176456	A1	20040909	US 2003-726878		20031202
CA 2509611	AA	20040701	CA 2003-2509611		20031203
AU 2003283708	A1	20040709	AU 2003-283708		20031203
EP 1572183	A1	20050914	EP 2003-775689		20031203
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
BR 2003016753	A	20051025	BR 2003-16753		20031203
CN 1726015	A	20060125	CN 2003-80105968		20031203
CN 1726021	A	20060125	CN 2003-80106009		20031203
JP 2006515587	T2	20060601	JP 2004-560041		20031203
US 2004132636	A1	20040708	US 2003-731605		20031209
US 2004180958	A1	20040916	US 2003-732613		20031210
US 2004143014	A1	20040722	US 2003-735398		20031212
PRIORITY APPLN. INFO.:			US 2002-433491P	P	20021213
			GB 2003-2657	A	20030205
			US 2003-454074P	P	20030312
			WO 2003-IB5682	W	20031203

OTHER SOURCE(S): MARPAT 141:88858
GRAPHIC IMAGE:



I



II

ABSTRACT:
The invention relates to a preparation of aminocarboxylic acid derivs., e.g. I [wherein: R1, R2, R3, R4, R5, R6, R7, and R8 are independently selected from H or C1-6alkyl, or R8 and R6 or R6 and R4 are taken together to form C3-7 cycloalkyl ring, etc.; n = 0-2; X is a carboxylic acid or carboxylic acid bioisostere], as alpha-2-delta ligands, useful for the treatment of premature ejaculation. For instance, delayed ejaculation in the presence of alpha-2-delta ligand II and effect of compound II on copulatory behavior in rapid ejaculating rats were demonstrated. Compound II increased ejaculation latency by 58% in rapidly ejaculating conscious rats.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> DIS L4 15 IBIB IABS
THE ESTIMATED COST FOR THIS REQUEST IS 2.74 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L4 ANSWER 15 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:531340 CAPLUS
DOCUMENT NUMBER: 141:89004
TITLE: Use of alpha-2-delta ligands to treat lower urinary tract symptoms associated with overactive bladder or benign prostatic hyperplasia, and the preparation of 4-substituted pyrrolidine-2-carboxylic acid derivatives and other compounds as ligands for such use
INVENTOR(S): Taylor, Charles Price, Jr.; Thorpe, Andrew John; Westbrook, Simon Lempriere; Wustrow, David Juergen
PATENT ASSIGNEE(S): Warner-Lambert Company Llc, USA
SOURCE: PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004054560	A1	20040701	WO 2003-IB5729	20031203
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2509605	AA	20040701	CA 2003-2509605	20031203
AU 2003303041	A1	20040709	AU 2003-303041	20031203
EP 1572173	A1	20050914	EP 2003-813233	20031203
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003016572	A	20051004	BR 2003-16572	20031203
CN 1720029	A	20060111	CN 2003-80105291	20031203
JP 2006511606	T2	20060406	JP 2005-502472	20031203
US 2004180958	A1	20040916	US 2003-732613	20031210
NO 2005003355	A	20050711	NO 2005-3355	20050711

PRIORITY APPLN. INFO.:	US 2002-433491P	P	20021213
	GB 2003-2657	A	20030205
	US 2003-454074P	P	20030312
	WO 2003-IB5729	W	20031203

OTHER SOURCE(S): MARPAT 141:89004
GRAPHIC IMAGE:



I

ABSTRACT:
Disclosed is the use of an alpha-2-delta ligand, or a pharmaceutically

acceptable derivative thereof, for the manufacture of a medicament for the treatment of
lower urinary tract symptoms (LUTS), other than urinary incontinence, which are associated with overactive bladder (OAB) and/or benign prostatic hyperplasia (BPH). Such use of approx. 35 specific compds. and/or their derivs. is claimed. For instance, (2S,4R)-4-hydroxypyrrolidine-1,2-dicarboxylic acid 1-tert-Bu 2-Me ester was etherified with 3-chlorophenol under Mitsunobu conditions (86%), followed by saponification of the Me ester with LiOH in aqueous THF
(98%), and hydrolysis of the tert-Bu ester with HCl in dioxane/THF (86.7%), to give acid I, a use-claimed ligand, as the HCl salt, on a 7-kg scale. In tests of gabapentin, a well-known alpha-2-delta ligand, on the micturition reflex of anesthetized rats, a significant, dose-dependent increase in interval between voiding episodes was observed relative to control animals, with a reduction in voids per h from approx. 5 to <1.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> DIS L4 16 IBIB IABS
THE ESTIMATED COST FOR THIS REQUEST IS 2.74 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L4 ANSWER 16 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:513533 CAPLUS
DOCUMENT NUMBER: 141:47364
TITLE: Prodrugs of fused GABA analogs, pharmaceutical compositions and uses thereof
INVENTOR(S): Gallop, Mark A.
PATENT ASSIGNEE(S): Xenoport, Inc., USA
SOURCE: PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004052360	A1	20040624	WO 2003-US39701		20031211
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2003297927	A1	20040630	AU 2003-297927		20031211
US 2004147455	A1	20040729	US 2003-734689		20031211
US 7060727	B2	20060613			
PRIORITY APPLN. INFO.:			US 2002-432871P	P	20021211
			US 2002-433216P	P	20021212
			WO 2003-US39701	W	20031211

OTHER SOURCE(S): MARPAT 141:47364
ABSTRACT:
The present invention relates generally to prodrugs of fused GABA analogs, pharmaceutical compns. of prodrugs of fused GABA analogs, methods of making prodrugs of fused GABA analogs and methods of using prodrugs of fused GABA analogs and pharmaceutical compns. of prodrugs of fused GABA analogs to treat or prevent various diseases. Claimed compds. include (1α,3α,5α)(3-aminomethylbicyclo[3.2.0]hept-3-yl)acetic acid

and [(1S,5S,6R)-6-aminomethylbicyclo[3.2.0]hept-6-yl]acetic acid.

=> DIS L4 17 IBIB IABS
THE ESTIMATED COST FOR THIS REQUEST IS 2.74 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L4 ANSWER 17 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:308400 CAPLUS
DOCUMENT NUMBER: 140:287120
TITLE: Preparation of cyclic nitromethyl acetic acid derivatives
INVENTOR(S): Derrick, Andrew Michael
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: PCT Int. Appl., 35 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004031124	A1	20040415	WO 2003-IB4249	20030922
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2498186	AA	20040415	CA 2003-2498186	20030922
AU 2003263517	A1	20040423	AU 2003-263517	20030922
EP 1556334	A1	20050727	EP 2003-799026	20030922
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003014954	A	20050802	BR 2003-14954	20030922
JP 2006501297	T2	20060112	JP 2004-541074	20030922
US 2004116525	A1	20040617	US 2003-677837	20031002
US 6911555	B2	20050628		

PRIORITY APPLN. INFO.:	GB 2002-23072	A	20021004
	US 2002-421867P	P	20021028
	WO 2003-IB4249	W	20030922

OTHER SOURCE(S): MARPAT 140:287120
ABSTRACT:
The invention relates cyclic nitromethyl acetic acid derivs. for use as intermediates in the preparation of cyclic and bicyclic amino acids. Salts of (1R,5R,6S)-[6-(nitromethyl)bicyclo[3.2.0]hept-6-yl]acetic acid (I) or the racemate are claimed. Thus, condensation of (1R,5R)-bicyclo[3.2.0]heptan-6-one with tri-Et phosphonoacetate, followed by reaction with nitromethane and saponification, afforded nitro acid I, which was converted to the cyclohexylamine salt.
Reduction of the nitro group by hydrogenation over Pt/C afforded (1R,5R,6S)-[6-(aminomethyl)bicyclo[3.2.0]hept-6-yl]acetic acid.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> DIS L4 18 IBIB IABS
THE ESTIMATED COST FOR THIS REQUEST IS 2.74 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:308394 CAPLUS
DOCUMENT NUMBER: 140:287119
TITLE: Preparation of bicyclo[3.2.0]hept-6-ylideneacetate intermediates in the synthesis of therapeutic fused bicyclic amino acids
INVENTOR(S): Gladwell, Iain Robert; Pettman, Alan John
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004031115	A1	20040415	WO 2003-IB4179	20030922
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2499863	AA	20040415	CA 2003-2499863	20030922
AU 2003263487	A1	20040423	AU 2003-263487	20030922
EP 1551789	A1	20050713	EP 2003-799019	20030922
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003015046	A	20050816	BR 2003-15046	20030922
JP 2006501296	T2	20060112	JP 2004-541065	20030922
US 2004138498	A1	20040715	US 2003-677836	20031002
US 7018818	B2	20060328		

PRIORITY APPLN. INFO.:

GB 2002-23070	A	20021004
US 2002-421868P	P	20021028
WO 2003-IB4179	W	20030922

OTHER SOURCE(S): MARPAT 140:287119
GRAPHIC IMAGE:



I



II

ABSTRACT:
The invention presents compds. I (R is H or a suitable carboxylic acid-protecting group) or stereoisomers and their ring-saturated derivs., which are intermediates in the preparation of therapeutic fused bicyclic amino acids. The synthesis comprises reaction of bicyclo[3.2.0]hept-2-en-6-one or bicyclo[3.2.0]heptan-6-one with a phosphonoacetate derivative In the examples, (±)-Et bicyclo[3.2.0]hept-6-ylideneacetate was prepared from bicyclo[3.2.0]heptan-6-one and tri-Et phosphonoacetate and underwent subsequent

enzymic hydrolysis, esterification, nitromethylation, saponification, and hydrogenation
to afford bicyclic amino acid II.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> DIS L4 19 IBIB IABS
THE ESTIMATED COST FOR THIS REQUEST IS 2.74 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:162589 CAPLUS
DOCUMENT NUMBER: 140:193110
TITLE: Fused bicyclic or tricyclic amino acids, their preparation, and their use in the treatment of fibromyalgia
INVENTOR(S): Blakemore, David Clive; Bryans., Kistom. Stephen; Williams, Sophie Caroline
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.; Bryans. Kistom. Stephen
SOURCE: PCT Int. Appl., 77 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004016260	A1	20040226	WO 2003-IB3546		20030806
WO 2004016260	C1	20040910			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2494811	AA	20040226	CA 2003-2494811		20030806
AU 2003250481	A1	20040303	AU 2003-250481		20030806
EP 1545491	A1	20050629	EP 2003-787963		20030806
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
BR 2003013432	A	20050712	BR 2003-13432		20030806
JP 2005539092	T2	20051222	JP 2005-502021		20030806
US 2004092591	A1	20040513	US 2003-640547		20030813
PRIORITY APPLN. INFO.:			GB 2002-19024	A	20020815
			GB 2002-23067	A	20021004
			US 2002-421866P	P	20021028
			WO 2003-IB3546	W	20030806

OTHER SOURCE(S): MARPAT 140:193110
ABSTRACT:
The compds. of the invention are bicyclic or tricyclic amino acids useful in the treatment of fibromyalgia. Pharmaceutical compns. containing one or more of the compds. for use in the treatment of fibromyalgia are also included.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> DIS L4 20 IBIB IABS
THE ESTIMATED COST FOR THIS REQUEST IS 2.74 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L4 ANSWER 20 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:162588 CAPLUS
DOCUMENT NUMBER: 140:210798
TITLE: Synergistic combination of an α2δ ligand and a PDEV inhibitor for use in the treatment of pain
INVENTOR(S): Field, Mark John; Williams, Richard Griffith
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: PCT Int. Appl., 96 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004016259	A1	20040226	WO 2003-IB3476		20030804
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2495433	AA	20040226	CA 2003-2495433		20030804
AU 2003249476	A1	20040303	AU 2003-249476		20030804
EP 1536782	A1	20050608	EP 2003-787957		20030804
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
BR 2003013484	A	20050621	BR 2003-13484		20030804
JP 2006502139	T2	20060119	JP 2004-528754		20030804
US 2004092591	A1	20040513	US 2003-640547		20030813
NO 2005000782	A	20050408	NO 2005-782		20050214
PRIORITY APPLN. INFO.:			GB 2002-19024	A	20020815
			GB 2002-23067	A	20021004
			US 2002-421866P	P	20021028
			WO 2003-IB3476	W	20030804

ABSTRACT:
The invention relates to a combination of an α2δ ligand and a PDEV inhibitor for use in therapy, particularly in the curative, prophylactic or palliative treatment of pain, particularly neuropathic pain. Particularly preferred α2δ α2δ α2δ ligands are
gabapentin and pregabalin. Particularly preferred PDEV inhibitors are sildenafil, vardenafil and tadalafil. Combinations of gabapentin and sildenafil on CCI-induced allodynia showed synergic effects over those effects with the drugs administered alone. (3S,5R)-3-amino-5-methyloctanoic acid was prepared as an example of an α2δ ligand.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> DIS L4 21 IBIB IABS
THE ESTIMATED COST FOR THIS REQUEST IS 2.74 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L4 ANSWER 21 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:678656 CAPLUS

DOCUMENT NUMBER: 139:202522
TITLE: Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2
INVENTOR(S): Taylor, Charles Price, Jr.
PATENT ASSIGNEE(S): Warner-Lambert Company LLC, USA
SOURCE: PCT Int. Appl., 135 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2003070237	A1	20030828	WO 2003-IB534		20030212
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2476438	AA	20030828	CA 2003-2476438		20030212
AU 2003246864	A1	20030909	AU 2003-246864		20030212
EP 1480639	A1	20041201	EP 2003-742460		20030212
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
BR 2003007906	A	20041221	BR 2003-7906		20030212
CN 1635887	A	20050706	CN 2003-804356		20030212
JP 2005523281	T2	20050804	JP 2003-569193		20030212
US 2003199567	A1	20031023	US 2003-366798		20030214
NO 2004003947	A	20040921	NO 2004-3947		20040921
PRIORITY APPLN. INFO.:			US 2002-359295P	P	20020222
			US 2002-404365P	P	20020819
			WO 2003-IB534	W	20030212

ABSTRACT:
The invention relates to a combination, comprising a selective inhibitor of COX-2, or a pharmaceutically acceptable salt thereof, and a ligand for calcium channel α2δ subunit, or a pharmaceutically acceptable salt thereof, and valdecoxib. Examples of selective inhibitors of COX-2 include valdecoxib, rofecoxib, and celecoxib. Examples of α2δ ligands include gabapentin, pregabalin, (3S,4S)-(1-aminomethyl-3,4-dimethyl-cyclopentyl)-acetic acid, and 3-(1-aminomethyl-cyclohexymethyl)-4H-[1,2,4]oxadiazol-5-one hydrochloride (I). The combinations are useful for treating certain diseases including cartilage damage, inflammation, pain, and arthritis. For example, capsules containing 25 mg each of valdecoxib and I were prepared

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> DIS L4 22 IBIB IABS
THE ESTIMATED COST FOR THIS REQUEST IS 2.74 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L4 ANSWER 22 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:832747 CAPLUS
DOCUMENT NUMBER: 137:338131
TITLE: Preparation of fused bicyclic or tricyclic amino acids
INVENTOR(S): Blakemore, David Clive; Bryans, Justin Stephen; Williams, Sophie Caroline
PATENT ASSIGNEE(S): Warner-Lambert Company, USA

SOURCE: PCT Int. Appl., 92 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2002085839	A1	20021031	WO 2002-IB1146		20020403
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
GB 2374595	A1	20021023	GB 2001-9635		20010419
CA 2444053	AA	20021031	CA 2002-2444053		20020403
EP 1379494	A1	20040114	EP 2002-716996		20020403
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
EE 200300517	A	20040415	EE 2003-517		20020403
BR 2002008922	A	20040420	BR 2002-8922		20020403
JP 2004527544	T2	20040909	JP 2002-583367		20020403
NZ 528151	A	20050429	NZ 2005-528151		20020403
CN 1720219	A	20060111	CN 2002-808445		20020403
US 2003078300	A1	20030424	US 2002-124210		20020416
US 6596900	B2	20030722			
ZA 2003007097	A	20040913	ZA 2003-7097		20030911
BG 108182	A	20040930	BG 2003-108182		20030917
NO 2003004642	A	20031209	NO 2003-4642		20031017
PRIORITY APPLN. INFO.:			GB 2001-9635	A	20010419
			GB 2001-25807	A	20011026
			WO 2002-IB1146	W	20020403

OTHER SOURCE(S): MARPAT 137:338131
ABSTRACT:
Bicyclic or tricyclic amino acids were prepared for use in the treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, arthritis, neuropathol. disorders, sleep disorders, visceral pain disorders, and gastrointestinal disorders. Pharmaceutical compns. containing one or more of the compds. are also included. Thus, [(1R,5R,6S)-6-(aminomethyl)bicyclo[3.2.0]hept-6-yl]acetic acid hydrochloride was prepared by treating Me [(1R,5R,6S)-6-(isocyanatomethyl)bicyclo[3.2.0]hept-6-yl]acetate with 6N HCl under reflux for 18 h. The isocyanate was obtained from bicyclo[3.2.0]hept-2-en-6-one by a multistep procedure, which includes reaction of (1RS, 5RS)-bicyclo[3.2.0]heptan-6-one with Et cyanoacetate.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	69.94	263.03

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-16.50	-17.25

FILE 'STNGUIDE' ENTERED AT 06:22:32 ON 25 AUG 2006

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Aug 18, 2006 (20060818/UP).

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.66	263.69

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-17.25

FILE 'REGISTRY' ENTERED AT 06:29:16 ON 25 AUG 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 23 AUG 2006 HIGHEST RN 904004-64-4
DICTIONARY FILE UPDATES: 23 AUG 2006 HIGHEST RN 904004-64-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>

=>
Uploading C:\Documents and Settings\mgraffeo\My Documents\Critical
Data\10726878\cmp 2.str





chain nodes :
5 6 7 8
ring nodes :
1 2 3 4 9 10 11 12
chain bonds :
3-5 3-7 5-6 7-8
ring bonds :
1-3 1-2 1-12 2-4 2-9 3-4 9-10 10-11 11-12
exact/norm bonds :
1-3 1-2 1-12 2-4 2-9 3-4 5-6 9-10 10-11 11-12

exact bonds :
3-5 3-7 7-8

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:Atom 10:Atom
 11:Atom 12:Atom

L6   STRUCTURE UPLOADED

=> s l6
SAMPLE SEARCH INITIATED 06:29:33 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   108 TO ITERATE

100.0% PROCESSED   108 ITERATIONS   1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS: 1537 TO   2783
PROJECTED ANSWERS: 1 TO   80

L7   1 SEA SSS SAM L6

=> s l6 full
FULL SEARCH INITIATED 06:29:37 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   2148 TO ITERATE

100.0% PROCESSED   2148 ITERATIONS   10 ANSWERS
SEARCH TIME: 00.00.01

L8   10 SEA SSS FUL L6

=> d 1-10

L8   ANSWER 1 OF 10 REGISTRY COPYRIGHT 2006 ACS on STN
RN   760140-93-0 REGISTRY
ED   Entered STN: 10 Oct 2004
CN   Bicyclo[4.2.0]octa-1,3,5-triene-7-acetic acid, 7-(aminomethyl)- (9CI) (CA
     INDEX NAME)
FS   3D CONCORD
MF   C11 H13 N O2
CI   COM
SR   CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8   ANSWER 2 OF 10 REGISTRY COPYRIGHT 2006 ACS on STN
RN   473829-58-2 REGISTRY
ED   Entered STN: 18 Nov 2002
CN   Bicyclo[4.2.0]octane-7-acetic acid, 7-(aminomethyl)-, (1R,6R,7R)-rel-
     (9CI) (CA INDEX NAME)

FS STEREOSEARCH
MF C11 H19 N O2
CI COM
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L8 ANSWER 3 OF 10 REGISTRY COPYRIGHT 2006 ACS on STN
RN 473829-57-1 REGISTRY
ED Entered STN: 18 Nov 2002
CN Bicyclo[4.2.0]octane-7-acetic acid, 7-(aminomethyl)-, (1R,6R,7S)-rel- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C11 H19 N O2
CI COM
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L8 ANSWER 4 OF 10 REGISTRY COPYRIGHT 2006 ACS on STN
RN 473829-42-4 REGISTRY
ED Entered STN: 18 Nov 2002
CN Bicyclo[4.2.0]octane-7-acetic acid, 7-(aminomethyl)-, (1S,6S,7R)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C11 H19 N O2
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L8 ANSWER 5 OF 10 REGISTRY COPYRIGHT 2006 ACS on STN
RN 473829-41-3 REGISTRY
ED Entered STN: 18 Nov 2002
CN Bicyclo[4.2.0]octane-7-acetic acid, 7-(aminomethyl)-, (1R,6R,7R)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C11 H19 N O2
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L8 ANSWER 6 OF 10 REGISTRY COPYRIGHT 2006 ACS on STN
RN 473829-40-2 REGISTRY
ED Entered STN: 18 Nov 2002
CN Bicyclo[4.2.0]octane-7-acetic acid, 7-(aminomethyl)-, (1S,6S,7S)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C11 H19 N O2
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L8 ANSWER 7 OF 10 REGISTRY COPYRIGHT 2006 ACS on STN
RN 473829-39-9 REGISTRY
ED Entered STN: 18 Nov 2002
CN Bicyclo[4.2.0]octane-7-acetic acid, 7-(aminomethyl)-, (1R,6R,7S)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C11 H19 N O2
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L8 ANSWER 8 OF 10 REGISTRY COPYRIGHT 2006 ACS on STN
RN 473829-36-6 REGISTRY
ED Entered STN: 18 Nov 2002
CN Bicyclo[4.2.0]octane-7-acetic acid, 7-(aminomethyl)-, hydrochloride, (1R,6R,7R)-rel- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C11 H19 N O2 . Cl H
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL
CRN (473829-58-2)

Relative stereochemistry.



● HCl

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L8 ANSWER 9 OF 10 REGISTRY COPYRIGHT 2006 ACS on STN
RN 473829-35-5 REGISTRY
ED Entered STN: 18 Nov 2002
CN Bicyclo[4.2.0]octane-7-acetic acid, 7-(aminomethyl)-, hydrochloride, (1R,6R,7S)-rel- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C11 H19 N O2 . Cl H
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL
CRN (473829-57-1)

Relative stereochemistry.



● HCl

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L8 ANSWER 10 OF 10 REGISTRY COPYRIGHT 2006 ACS on STN
RN 132205-59-5 REGISTRY
ED Entered STN: 22 Feb 1991
CN Bicyclo[4.2.0]octa-1,3,5-triene-7-acetic acid, 7-(aminomethyl)-, hydrochloride (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Bicyclo[4.2.0]octa-1,3,5-triene-7-acetic acid, 7-(aminomethyl)-, hydrochloride, (±)-
MF C11 H13 N O2 . Cl H

SR CA
LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT
        (*File contains numerically searchable property data)
CRN (760140-93-0)



● HCl

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	185.94	449.63

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-17.25

FILE 'CAPLUS' ENTERED AT 06:30:03 ON 25 AUG 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 25 Aug 2006 VOL 145 ISS 9
FILE LAST UPDATED: 23 Aug 2006 (20060823/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l8
L9 6 L8

=> s l9 and (ejeculat? or erectile)
  6 EJECULAT?
2587 ERECTILE
L10 0 L9 AND (EJECULAT? OR ERECTILE)

```
=> s l9 and (ejaculat? or erectile)
          5209 EJACULAT?
          2587 ERECTILE
L11          1 L9 AND (EJACULAT? OR ERECTILE)

=> d

L11  ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2006 ACS on STN
AN   2004:531342  CAPLUS
DN   141:88858
TI   A preparation of aminocarboxylic acid derivatives as alpha-2-delta
     ligands, useful for the treatment of sexual dysfunction
IN   Taylor, Charles Price, Jr; Thorpe, Andrew John; Van Der Graaf, Pieter
     Hadewijn; Wayman, Christopher Peter; Wustrow, David Juergen
PA   Warner-Lambert Company LLC, USA
SO   PCT Int. Appl., 39 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 9
     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
PI   WO 2004054563         A1    20040701    WO 2003-IB5682          20031203
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
             GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
             LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
             OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
             TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
             ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
             TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     CA 2451267           AA    20040613    CA 2003-2451267         20031127
     US 2004176456        A1    20040909    US 2003-726878          20031202
     CA 2509611           AA    20040701    CA 2003-2509611         20031203
     AU 2003283708        A1    20040709    AU 2003-283708          20031203
     EP 1572183           A1    20050914    EP 2003-775689          20031203
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     BR 2003016753        A     20051025    BR 2003-16753           20031203
     CN 1726015           A     20060125    CN 2003-80105968        20031203
     CN 1726021           A     20060125    CN 2003-80106009        20031203
     JP 2006515587        T2    20060601    JP 2004-560041          20031203
     US 2004132636        A1    20040708    US 2003-731605          20031209
     US 2004180958        A1    20040916    US 2003-732613          20031210
     US 2004143014        A1    20040722    US 2003-735398          20031212
PRAI US 2002-433491P      P     20021213
     GB 2003-2657         A     20030205
     US 2003-454074P      P     20030312
     WO 2003-IB5682       W     20031203
OS   MARPAT 141:88858
RE.CNT  2     THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> s l9
L12          6 L8

=> d 1-6 bib abs hitstr

L12  ANSWER 1 OF 6  CAPLUS  COPYRIGHT 2006 ACS on STN
AN   2005:493505  CAPLUS
DN   143:32337
TI   Calcium carbonate for stabilizing solid pharmaceutical compositions of
```

amino acids
IN Razzano, Elena
PA Pfizer Limited, UK; Pfizer Inc.
SO PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005051384	A1	20050609	WO 2004-IB3743	20041112

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI	GB 2003-27389	A	20031125
	US 2004-535845P	P	20040112

OS MARPAT 143:32337
AB The present invention relates to the use of calcium carbonate as a stabilizing agent in solid pharmaceutical compns. comprising an amino acid as the pharmaceutically active agent, to the stabilized pharmaceutical compns. resulting therefrom and processes for their preparation Thus, tablets were prepared containing (+)-(2S)-5-amino-2-[(1-n-propyl-1H-imidazol-4-yl)methyl]pentanoic acid (active component) 31.13 mg, microcryst. cellulose 32.31 mg, calcium carbonate 32.31 mg, croscarmellose sodium 3.00 mg, and magnesium stearate 1.25 mg. Tablets stored at 40° and 75% relative humidity for 12 wk showed the presence of 98.9% of the active component.
IT 473829-39-9 473829-40-2 473829-41-3
473829-42-4
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(calcium carbonate stabilization of amino acid-containing solid dosage forms)
RN 473829-39-9 CAPLUS
CN Bicyclo[4.2.0]octane-7-acetic acid, 7-(aminomethyl)-, (1R,6R,7S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 473829-40-2 CAPLUS
CN Bicyclo[4.2.0]octane-7-acetic acid, 7-(aminomethyl)-, (1S,6S,7S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 473829-41-3 CAPLUS
CN Bicyclo[4.2.0]octane-7-acetic acid, 7-(aminomethyl)-, (1R,6R,7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 473829-42-4 CAPLUS
CN Bicyclo[4.2.0]octane-7-acetic acid, 7-(aminomethyl)-, (1S,6S,7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:531342 CAPLUS
DN 141:88858
TI A preparation of aminocarboxylic acid derivatives as alpha-2-delta ligands, useful for the treatment of sexual dysfunction
IN Taylor, Charles Price, Jr; Thorpe, Andrew John; Van Der Graaf, Pieter Hadewijn; Wayman, Christopher Peter; Wustrow, David Juergen
PA Warner-Lambert Company LLC, USA
SO PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 9

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004054563	A1	20040701	WO 2003-IB5682	20031203

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

	CA 2451267	AA	20040613	CA 2003-2451267	20031127
	US 2004176456	A1	20040909	US 2003-726878	20031202
	CA 2509611	AA	20040701	CA 2003-2509611	20031203
	AU 2003283708	A1	20040709	AU 2003-283708	20031203
	EP 1572183	A1	20050914	EP 2003-775689	20031203
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003016753	A	20051025	BR 2003-16753	20031203
	CN 1726015	A	20060125	CN 2003-80105968	20031203
	CN 1726021	A	20060125	CN 2003-80106009	20031203
	JP 2006515587	T2	20060601	JP 2004-560041	20031203
	US 2004132636	A1	20040708	US 2003-731605	20031209
	US 2004180958	A1	20040916	US 2003-732613	20031210
	US 2004143014	A1	20040722	US 2003-735398	20031212
PRAI	US 2002-433491P	P	20021213		
	GB 2003-2657	A	20030205		
	US 2003-454074P	P	20030312		
	WO 2003-IB5682	W	20031203		

OS MARPAT 141:88858

GI



I



II

AB The invention relates to a preparation of aminocarboxylic acid derivs., e.g. I [wherein: R1, R2, R3, R4, R5, R6, R7, and R8 are independently selected from H or C1-6alkyl, or R8 and R6 or R6 and R4 are taken together to form C3-7 cycloalkyl ring, etc.; n = 0-2; X is a carboxylic acid or carboxylic acid bioisostere], as alpha-2-delta ligands, useful for the treatment of premature ejaculation. For instance, delayed ejaculation in the presence of alpha-2-delta ligand II and effect of compound II on copulatory behavior in rapid ejaculating rats were demonstrated. Compound II increased ejaculation latency by 58% in rapidly ejaculating conscious rats.

IT 473829-39-9P 473829-40-2P 473829-41-3P
473829-42-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aminocarboxylic acid derivs. as alpha-2-delta ligands, useful for the treatment of sexual dysfunction)

RN 473829-39-9 CAPLUS

CN Bicyclo[4.2.0]octane-7-acetic acid, 7-(aminomethyl)-, (1R,6R,7S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 473829-40-2 CAPLUS
CN Bicyclo[4.2.0]octane-7-acetic acid, 7-(aminomethyl)-, (1S,6S,7S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 473829-41-3 CAPLUS
CN Bicyclo[4.2.0]octane-7-acetic acid, 7-(aminomethyl)-, (1R,6R,7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 473829-42-4 CAPLUS
CN Bicyclo[4.2.0]octane-7-acetic acid, 7-(aminomethyl)-, (1S,6S,7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:531340 CAPLUS
DN 141:89004
TI Use of alpha-2-delta ligands to treat lower urinary tract symptoms associated with overactive bladder or benign prostatic hyperplasia, and the preparation of 4-substituted pyrrolidine-2-carboxylic acid derivatives and other compounds as ligands for such use
IN Taylor, Charles Price, Jr.; Thorpe, Andrew John; Westbrook, Simon Lempriere; Wustrow, David Juergen
PA Warner-Lambert Company Llc, USA
SO PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 9

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004054560	A1	20040701	WO 2003-IB5729	20031203
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2509605	AA	20040701	CA 2003-2509605	20031203
	AU 2003303041	A1	20040709	AU 2003-303041	20031203
	EP 1572173	A1	20050914	EP 2003-813233	20031203
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003016572	A	20051004	BR 2003-16572	20031203
	CN 1720029	A	20060111	CN 2003-80105291	20031203
	JP 2006511606	T2	20060406	JP 2005-502472	20031203
	US 2004180958	A1	20040916	US 2003-732613	20031210
	NO 2005003355	A	20050711	NO 2005-3355	20050711
PRAI	US 2002-433491P	P	20021213		
	GB 2003-2657	A	20030205		
	US 2003-454074P	P	20030312		
	WO 2003-IB5729	W	20031203		

OS MARPAT 141:89004
GI



I

AB Disclosed is the use of an alpha-2-delta ligand, or a pharmaceutically acceptable derivative thereof, for the manufacture of a medicament for the treatment of lower urinary tract symptoms (LUTS), other than urinary incontinence, which are associated with overactive bladder (OAB) and/or benign prostatic hyperplasia (BPH). Such use of approx. 35 specific

compds. and/or their derivs. is claimed. For instance, (2S,4R)-4-hydroxypyrrolidine-1,2-dicarboxylic acid 1-tert-Bu 2-Me ester was etherified with 3-chlorophenol under Mitsunobu conditions (86%), followed by saponification of the Me ester with LiOH in aqueous THF (98%), and hydrolysis of the tert-Bu ester with HCl in dioxane/THF (86.7%), to give acid I, a use-claimed ligand, as the HCl salt, on a 7-kg scale. In tests of gabapentin, a well-known alpha-2-delta ligand, on the micturition reflex of anesthetized rats, a significant, dose-dependent increase in interval between voiding episodes was observed relative to control animals, with a reduction in voids per h from approx. 5 to <1.

IT 473829-39-9 473829-40-2 473829-41-3
473829-42-4
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(drug use candidate; preparation of alpha-2-delta ligands to treat lower urinary tract symptoms)

RN 473829-39-9 CAPLUS
CN Bicyclo[4.2.0]octane-7-acetic acid, 7-(aminomethyl)-, (1R,6R,7S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 473829-40-2 CAPLUS
CN Bicyclo[4.2.0]octane-7-acetic acid, 7-(aminomethyl)-, (1S,6S,7S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 473829-41-3 CAPLUS
CN Bicyclo[4.2.0]octane-7-acetic acid, 7-(aminomethyl)-, (1R,6R,7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 473829-42-4 CAPLUS
CN Bicyclo[4.2.0]octane-7-acetic acid, 7-(aminomethyl)-, (1S,6S,7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:162589 CAPLUS
DN 140:193110
TI Fused bicyclic or tricyclic amino acids, their preparation, and their use in the treatment of fibromyalgia
IN Blakemore, David Clive; Bryans., Kistom. Stephen; Williams, Sophie Caroline
PA Pfizer Limited, UK; Pfizer Inc.; Bryans. Kistom. Stephen
SO PCT Int. Appl., 77 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004016260	A1	20040226	WO 2003-IB3546	20030806
	WO 2004016260	C1	20040910		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2494811	AA	20040226	CA 2003-2494811	20030806
	AU 2003250481	A1	20040303	AU 2003-250481	20030806
	EP 1545491	A1	20050629	EP 2003-787963	20030806
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003013432	A	20050712	BR 2003-13432	20030806

	JP 2005539092	T2	20051222	JP 2005-502021	20030806
	US 2004092591	A1	20040513	US 2003-640547	20030813
PRAI	GB 2002-19024	A	20020815		
	GB 2002-23067	A	20021004		
	US 2002-421866P	P	20021028		
	WO 2003-IB3546	W	20030806		

OS MARPAT 140:193110

AB The compds. of the invention are bicyclic or tricyclic amino acids useful in the treatment of fibromyalgia. Pharmaceutical compns. containing one or more of the compds. for use in the treatment of fibromyalgia are also included.

IT 473829-35-5P 473829-36-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(fused bicyclic or tricyclic amino acid preparation and use in treatment of fibromyalgia)

RN 473829-35-5 CAPLUS

CN Bicyclo[4.2.0]octane-7-acetic acid, 7-(aminomethyl)-, hydrochloride, (1R,6R,7S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 473829-36-6 CAPLUS

CN Bicyclo[4.2.0]octane-7-acetic acid, 7-(aminomethyl)-, hydrochloride, (1R,6R,7R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

IT 473829-39-9 473829-40-2 473829-41-3
473829-42-4 473829-57-1 473829-58-2
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(fused bicyclic or tricyclic amino acid preparation and use in treatment of fibromyalgia)

RN 473829-39-9 CAPLUS
CN Bicyclo[4.2.0]octane-7-acetic acid, 7-(aminomethyl)-, (1R,6R,7S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 473829-40-2 CAPLUS
CN Bicyclo[4.2.0]octane-7-acetic acid, 7-(aminomethyl)-, (1S,6S,7S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 473829-41-3 CAPLUS
CN Bicyclo[4.2.0]octane-7-acetic acid, 7-(aminomethyl)-, (1R,6R,7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 473829-42-4 CAPLUS
CN Bicyclo[4.2.0]octane-7-acetic acid, 7-(aminomethyl)-, (1S,6S,7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 473829-57-1 CAPLUS
CN Bicyclo[4.2.0]octane-7-acetic acid, 7-(aminomethyl)-, (1R,6R,7S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 473829-58-2 CAPLUS
CN Bicyclo[4.2.0]octane-7-acetic acid, 7-(aminomethyl)-, (1R,6R,7R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:832747 CAPLUS
DN 137:338131
TI Preparation of fused bicyclic or tricyclic amino acids
IN Blakemore, David Clive; Bryans, Justin Stephen; Williams, Sophie Caroline
PA Warner-Lambert Company, USA
SO PCT Int. Appl., 92 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002085839	A1	20021031	WO 2002-IB1146	20020403

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

	GB 2374595	A1	20021023	GB 2001-9635	20010419
	CA 2444053	AA	20021031	CA 2002-2444053	20020403
	EP 1379494	A1	20040114	EP 2002-716996	20020403
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	EE 200300517	A	20040415	EE 2003-517	20020403
	BR 2002008922	A	20040420	BR 2002-8922	20020403
	JP 2004527544	T2	20040909	JP 2002-583367	20020403
	NZ 528151	A	20050429	NZ 2005-528151	20020403
	CN 1720219	A	20060111	CN 2002-808445	20020403
	US 2003078300	A1	20030424	US 2002-124210	20020416
	US 6596900	B2	20030722		
	ZA 2003007097	A	20040913	ZA 2003-7097	20030911
	BG 108182	A	20040930	BG 2003-108182	20030917
	NO 2003004642	A	20031209	NO 2003-4642	20031017
PRAI	GB 2001-9635	A	20010419		
	GB 2001-25807	A	20011026		
	WO 2002-IB1146	W	20020403		

OS MARPAT 137:338131

AB Bicyclic or tricyclic amino acids were prepared for use in the treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, arthritis, neuropathol. disorders, sleep disorders, visceral pain disorders, and gastrointestinal disorders. Pharmaceutical compns. containing one or more of the compds. are also included. Thus, [(1R,5R,6S)-6-(aminomethyl)bicyclo[3.2.0]hept-6-yl]acetic acid hydrochloride was prepared by treating Me [(1R,5R,6S)-6-(isocyanatomethyl)bicyclo[3.2.0]hept-6-yl]acetate with 6N HCl under reflux for 18 h. The isocyanate was obtained from bicyclo[3.2.0]hept-2-en-6-one by a multistep procedure, which includes reaction of (1RS, 5RS)-bicyclo[3.2.0]heptan-6-one with Et cyanoacetate.

IT 473829-35-5P 473829-36-6P 473829-39-9P
473829-40-2P 473829-41-3P 473829-42-4P
473829-57-1P 473829-58-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of fused bicyclic or tricyclic amino acids)

RN 473829-35-5 CAPLUS

CN Bicyclo[4.2.0]octane-7-acetic acid, 7-(aminomethyl)-, hydrochloride, (1R,6R,7S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 473829-36-6 CAPLUS
CN Bicyclo[4.2.0]octane-7-acetic acid, 7-(aminomethyl)-, hydrochloride, (1R,6R,7R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 473829-39-9 CAPLUS
CN Bicyclo[4.2.0]octane-7-acetic acid, 7-(aminomethyl)-, (1R,6R,7S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 473829-40-2 CAPLUS
CN Bicyclo[4.2.0]octane-7-acetic acid, 7-(aminomethyl)-, (1S,6S,7S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 473829-41-3 CAPLUS
CN Bicyclo[4.2.0]octane-7-acetic acid, 7-(aminomethyl)-, (1R,6R,7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 473829-42-4 CAPLUS
CN Bicyclo[4.2.0]octane-7-acetic acid, 7-(aminomethyl)-, (1S,6S,7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 473829-57-1 CAPLUS
CN Bicyclo[4.2.0]octane-7-acetic acid, 7-(aminomethyl)-, (1R,6R,7S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 473829-58-2 CAPLUS
CN Bicyclo[4.2.0]octane-7-acetic acid, 7-(aminomethyl)-, (1R,6R,7R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1991:184942 CAPLUS
DN 114:184942
TI Synthesis and biochemical evaluation of baclofen analogs locked in the baclofen solid-state conformation
AU Mann, Andre; Boulanger, Thierry; Brandau, Barbara; Durant, Francois; Evrard, Guy; Heaulme, Michel; Desaulles, Eric; Wermuth, Camille Georges
CS Dep. Pharmacochim. Mol., Cent. Neurochim., Strasbourg, 67084, Fr.
SO Journal of Medicinal Chemistry (1991), 34(4), 1307-13
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
OS CASREACT 114:184942
GI



I



II

AB The synthesis of six close analogs of baclofen [3-(4-chlorophenyl)-4-aminobutyric acid] (BAC), a potent GABAB agonist, are reported. The compds. were designed starting from the structural informations contained in the solid state of BAC, regarded as a possible bioactive conformation, in which the p-chlorophenyl ring is perpendicular to the GABA backbone. A similar conformational situation was created by rigidifying the BAC structure by means of methylene, ethylene, or propylene units, or by introducing chlorine atoms into the ortho positions ("ortho effect"). Only compound I showed affinity for the GABAB receptor. Compound II, which was initially considered as representing the optimal mimic of the solid-state conformation of BAC, was surprisingly found inactive. An extensive conformational anal. was performed in order to evaluate their flexibility and the overlap of their conformational population with respect to BAC. For this purpose a distance map was generated from three possible pharmacophoric groups: the amino and the carboxylic functions, and the Ph ring. Finally, several explanations are proposed to account for the poor affinities of the prepared compds. such as steric hindrance or flexibility demand of the receptor.
IT 132205-59-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and binding by, of GABA receptor)
RN 132205-59-5 CAPLUS
CN Bicyclo[4.2.0]octa-1,3,5-triene-7-acetic acid, 7-(aminomethyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

```
=> d his

     (FILE 'HOME' ENTERED AT 06:01:18 ON 25 AUG 2006)

     FILE 'REGISTRY' ENTERED AT 06:03:09 ON 25 AUG 2006
L1             STRUCTURE UPLOADED
L2           1 S L1
L3           9 S L2 FULL

     FILE 'CAPLUS' ENTERED AT 06:04:08 ON 25 AUG 2006
L4          22 S L3
L5           1 S L4 AND (ERECTILE OR EJACULATION)

     FILE 'STNGUIDE' ENTERED AT 06:05:31 ON 25 AUG 2006

     FILE 'CAPLUS' ENTERED AT 06:09:39 ON 25 AUG 2006

     FILE 'STNGUIDE' ENTERED AT 06:22:32 ON 25 AUG 2006

     FILE 'REGISTRY' ENTERED AT 06:29:16 ON 25 AUG 2006
L6             STRUCTURE UPLOADED
L7           1 S L6
L8          10 S L6 FULL

     FILE 'CAPLUS' ENTERED AT 06:30:03 ON 25 AUG 2006
L9           6 S L8
L10          0 S L9 AND (EJECULAT? OR ERECTILE)
L11          1 S L9 AND (EJACULAT? OR ERECTILE)
L12          6 S L9

=>

---Logging off of STN---


=>
Executing the logoff script...


=> LOG Y

COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                52.02     501.65

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)      SINCE FILE      TOTAL
                                                   ENTRY    SESSION
CA SUBSCRIBER PRICE                                -4.50     -21.75

STN INTERNATIONAL LOGOFF AT 06:46:06 ON 25 AUG 2006
```